Poniard To Release More Trial Data
Poniard Pharmaceuticals Inc. (Nasdaq: PARD) will release more data on Monday from a Phase 2 clinical trial of its colorectal cancer treatment picoplatin sending the stock price soaring 47 cents to close at $2.61.
Poniard Pharmaceuticals Inc. (Nasdaq: PARD) will release more data on Monday from a Phase 2 clinical trial of its colorectal cancer treatment picoplatin sending the stock price soaring 47 cents to close at $2.61.
